Business
Suda Pharmaceuticals share price soars 200% on TGA approval – Motley Fool Australia
The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.
The Suda Pharmaceuticals Ltd(ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administration). ZolpiMist is an oral spray for the treatment of insomnia.
In an investor presentation released by Suda Pharmaceuticals earlier this month, the company estimated the market for insomnia treatments will be approximately US$4 billion by 2026. Furthermore, a…
-
Noosa News22 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business23 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News21 hours agoAfter Hours Gallery Visits, French Dining and Garden Illuminations: Your Guide to the Ultimate Melbourne Culture Fix
-
General15 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people